about
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design ApproachInsight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFRStructure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor.Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer.Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.An Unusual Intramolecular Halogen Bond guides Conformational Selection.C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer TherapeuticsOvercoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsA novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivativesMetal-free direct oxidative intermolecular diarylation of anilides at ambient temperature assisted by cascade selective formation of C–C and C–N bondsOrganocatalytic, Oxidative, Intramolecular CH Bond Amination and Metal-free Cross-Amination of Unactivated Arenes at Ambient TemperatureTargeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) ConjugatesCharacterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797SStructure Defines Function: Clinically Relevant Mutations in ErbB Kinases
P50
Q27701812-A5111504-8067-48E7-9528-C61898EACFB7Q27725743-204F0636-75AF-4F03-93CA-4ECAB4C0A4ACQ38693812-50058296-D891-4946-AA3B-130697D09CADQ38700602-4C5FDB10-33E6-4CB0-9043-BAE6F8F42A65Q38715381-8FA76C10-ECDE-4E05-A15E-ACCC5AE422A5Q43083907-2F37906B-C640-4736-A795-8E5AF2214387Q48231295-F8460AC4-4723-4292-8CCB-58A3F6C121F0Q54976891-414841DD-F464-4DC0-97E1-7D22CE886008Q57174988-5C5B178B-EC6B-4FC9-97C9-B635E86C22D0Q57293866-E78DF90C-A808-467F-BDA3-E3DB0A0C7898Q58599659-8751A182-EBAE-47A4-8AED-72411669AC0EQ60915049-09F293CA-9644-4BBF-84C6-588BA329D1C6Q64027946-B5EB42B0-1692-40E6-97AE-3A90AD235AF5Q64027956-0C09C05E-2674-4723-ADEA-4576250C796CQ64925189-E6C0C7DD-019F-4005-AB2F-63D047E9AABEQ89174850-65B2C11B-04D4-4E03-9A10-4AEDC01FBEC9Q91985356-EBD9207A-778F-4DEC-8A66-D3946AD348B5Q92134225-0CD11EF2-9918-4215-A10E-FDB17BF9F4D8Q92634166-6B5289CF-3A9C-4210-825D-447D558C8EE1
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0001-5993-7082
@en
name
Jonas Lategahn
@ast
Jonas Lategahn
@en
Jonas Lategahn
@es
Jonas Lategahn
@nl
type
label
Jonas Lategahn
@ast
Jonas Lategahn
@en
Jonas Lategahn
@es
Jonas Lategahn
@nl
prefLabel
Jonas Lategahn
@ast
Jonas Lategahn
@en
Jonas Lategahn
@es
Jonas Lategahn
@nl
P106
P21
P31
P496
0000-0001-5993-7082